Stock FATE FATE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Revisions Fate Therapeutics, Inc.

Equities

FATE

US31189P1021

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
3.87 USD -10.00% Intraday chart for Fate Therapeutics, Inc. -23.21% +3.48%
Apr. 22 Fate Therapeutics, Inc. Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting CI
Mar. 21 Fate Therapeutics, Inc. announced that it has received $19.996366 million in funding from Redmile Group, LLC CI

Turnover - Change in analysts' estimates

Earnings Per Share (EPS) - Change in analysts' estimates

EBIT - Change in analysts' estimates

Dividend / Share (DPS) - Change in analysts' estimates

Cash or Net Debt - Change in analysts' estimates

Turnover

Earnings Per Share (EPS)

EBIT

Dividend / Share (DPS)

Cash or Net Debt

  1. Stock Market
  2. Equities
  3. FATE Stock
  4. Revisions Fate Therapeutics, Inc.